Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

• References

• 1 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
• 2 Gelehrter TD, Barouski Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983; 53-54: 11-21
• 3 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
• 4 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
• 5 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-6780
• 6 Chmielewska J, RAnby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for “second-site” interactions. Biochem J 1988; 251: 327-332
• 7 Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990; 265: 109-113
• 8 Hekman C, Loskutoff D. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
• 9 Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751
• 10 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273
• 11 Declerck PI, De Mol M, Alessi MC, Baudner S, Paques E, Preissner K, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461
• 12 Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-128
• 13 Seiffert D, Loskutoff D. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991; 266: 2824-2830
• 14 Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994; 1208: 104-110
• 15 Loskutoff DJ, Linders M, Keijer J, Veerman H, van Heerikhuizen H, Pannekoek H. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry 1987; 26: 3763-3768
• 16 Strandberg L, Lawrence D, Ny T. The organization of the human- plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988; 176: 609-616
• 17 van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis II. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
• 18 van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-5529
• 19 Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik KH, Alitalo K, Blasi F, Dano K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84: 8548-8552
• 20 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991; 11: 183-190
• 21 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745
• 22 Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991; 34: 179-192
• 23 Kluft C, Verheijen JH. The Leiden fibrinolysis working party. Blood collection and handling procedures for assessment of tissue- type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990; 4: 155-161
• 24 Wiman B, Haegerstrand-Bjorkman M. Plasmin/a₂-antiplasmin complex in plasma — a global fibrinolytic assay. Thromb Haemostas 1993; 69: 1091 Abstract no 1958;
• 25 Colucci M, Paramo JA, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
• 26 Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast-acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. I Exp Med 1986; 163: 1260-1266
• 27 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line HepG2. Thromb Haemostas 1988; 60: 491-494
• 28 Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type- 1: Implications for vascular disease by hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88: 9959-9963
• 29 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073
• 30 Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-1829
• 31 Tremoli E, Camera M, Madema P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor- independent phenomenon. Arterioscler Thromb 1993; 13: 338-346
• 32 Mussoni L, Mannucci L, Sirtori M, Camera M, Madema P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27
• 33 Hamsten A, Wiman B. Fibrinolysis and atherosclerotic cardiovascular disease. In: Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. Francis Jr. RB. (ed). Marcel Dekker, Inc.; New York: 1993. pp. 107-129
• 34 Caron P, Bennet A, Camare R, Louvet JP, Boneu S, Pie P. Plasminogen activator inhibitor in plasma in related to testosterone in men. Metabolism 1989; 38: 1010-1015
• 35 Yang XC, Jing TY, Resnick LM, Phillips GB. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993; 13: 167-171
• 36 Andreotti F, Davies GJ, Hackett DR, Khan MI, de Bart AC, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-637
• 37 Grimaudo V, Hauert J, Bachmann F, Kruithof EK O. Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495-499
• 38 Angelton P, Chandler WL, Schmer G. Diurnal variation of tissue- type plasminogen activator and its rapid inhibition. Circulation 1989; 79: 101-106
• 39 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 40 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
• 41 Juhan-Vague I, Vague P, Alessi M, Badier C, Valadier J, Aillaud M, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331-336
• 42 Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 3: 51-53
• 43 Andersen P, Smith P, Seljeflot I, Brataker S, Amesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemostas 1990; 63: 174-177
• 44 Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84: 25-32
• 45 Juhan-Vague I, Thompson SG, Jespersen J. On behalf of the ECAT angina pectoris study group. Involvement of the hemostatic system in the insulin resistance syndrome, a study of 15,000 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-1873
• 46 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462
• 47 Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-169
• 48 Angles Cano E, Gris JC, Loyau S, Schved JF. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. J Lab Clin Med 1993; 121: 646-653
• 49 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76
• 50 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De-Vos R, van-den-Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424
• 51 Paramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fastacting inhibitor — Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost 1985; 54: 713-716
• 52 Eriksson B, Eriksson E, Gyzander E, Teger-Nilsson AC, Thorsen S, Risberg B. Thrombosis after hip replacement, relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159-163
• 53 Mellbring G, Dahlgren S, Reiz S, Wiman B. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res 1983; 32: 575-584
• 54 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
• 55 Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93
• 56 Vandekerckhove Y, Baele G, de Puydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988; 50: 449-453
• 57 Aznar J, Estelles A, Torino G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541
• 58 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
• 59 Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Stand 1987; 221: 149-153
• 60 Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525-528
• 61 Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161
• 62 Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034
• 63 Ridker PM, Vaughan PE, Stampfer MJ, Manson JE, Hennehens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
• 64 Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. for the PLAT group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients - a case-control study. Arterioscler Thromb 1993; 13: 1412-1417
• 65 Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8 (Suppl. 01) 253-262